Incyte Q2 Revenue Jumps 38%, Raises 2026 Guidance on Broad-Based Strength
INCY sits 87% above its 52-week low of $69.695 on elevated volume (3.2× avg).
Summary
Incyte reported Q2 2026 revenue of $1.67 billion, up 38% year-over-year, and raised full-year guidance to $5.13-$5.26 billion. The quarter included a $246 million non-cash benefit from a CMS settlement on Opzelura.
Key Events · Earnings and Guidance · INCY
-
Revenue Surges 38% to $1.67B
Total Q2 2026 revenue reached $1.67 billion, driven by strong product sales including Jakafi ($816.7M), Opzelura ($449.7M, including a $246M CMS settlement benefit), and rapid growth from newer products like Monjuvi, Zynyz, and Niktimvo.
-
Full-Year 2026 Guidance Raised
Incyte lifted its 2026 revenue guidance to $5.13-$5.26 billion, up from $4.77-$4.94 billion, reflecting broad-based commercial momentum and the positive impact of the CMS settlement on Opzelura's gross-to-net.
-
Net Income More Than Doubles
Q2 net income was $585.6 million, or $2.81 per diluted share, compared to $405.0 million a year ago, driven by higher revenues and a lower effective tax rate.
-
Vega Therapeutics Acquisition Closed
On July 6, 2026, Incyte completed the $1.25 billion acquisition of Vega Therapeutics, adding latarcibart, a Phase 3 monoclonal antibody for von Willebrand disease, to its pipeline.
Analysis · INCY · Industrial Applications And Services
A standout quarter saw total revenue surge 38% year-over-year to $1.67 billion, fueled by robust product sales and a one-time $246 million benefit from a CMS settlement on Opzelura. Confidence in sustained momentum is evident as the company raised its full-year 2026 revenue guidance to $5.13-$5.26 billion, up from $4.77-$4.94 billion. Net income more than doubled to $585.6 million, and the balance sheet remains fortress-like with $4.5 billion in cash, even after closing the $1.25 billion Vega Therapeutics acquisition. The results underscore successful diversification beyond Jakafi, with Opzelura, Monjuvi, and Zynyz all posting triple-digit growth. The raised guidance and pipeline progress, including the Vega deal adding a Phase 3 asset in von Willebrand disease, position the company for continued expansion.
At the time of this filing, INCY was trading at $130.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $26B. The 52-week trading range was $69.70 to $132.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.